item management s discussion and analysis of financial condition and results of operations overview the following discussion of the financial condition and results of operations of the company should be read in conjunction with the financial statements and notes thereto included elsewhere in this form k 
the financial results for the years ended december  and and for the period from january  through november  are for the business of the company as conducted by the company s predecessor  the cytology and pathology automation business of roche image analysis systems  inc rias 
for purposes of this discussion  information for the year ended december  combines financial results of the company s predecessor and autocyte 
background autocyte was formed in october to acquire the cytology and pathology automation business then owned by rias  a wholly owned subsidiary of roche holding ltd 
roche 
roche had previously operated such business as part of roche biomedical reference laboratories  inc  a predecessor company to laboratory corporation of america  inc  the largest clinical laboratory chain in the united states and formerly a wholly owned subsidiary of roche 
the company cannot market its prep or screen systems in the united states for use in preparing or screening thin layer slides for cervical cancer until pma approvals are received from the fda 
if such approvals are obtained  the company intends to focus its marketing efforts on such products for cervical cytology applications 
the company expects to generate a substantial majority of its future revenues from the prep and screen systems 
the company s long term revenues and future success are substantially dependent upon its ability to obtain regulatory approval for  and market and commercialize the prep and screen systems for  cervical cancer screening in the united states and abroad 
the company generates prep revenue from both system sales and rentals 
for system sales  customers purchase the prep instrument and make separate purchases of related reagents and other disposables 
for system rentals  the company places the prep instrument at the customer s site  and customers make monthly payments that include rent and the purchase of a minimum monthly quantity of reagents and other disposables 
the term of the prep rentals ranges from month to month to three years 
for screen customers in the united states  the company intends to place instruments without charge at customer locations and to charge customers on a per test  or fee per use fpu  basis 
in foreign markets  the company plans to either sell or license screen 
as an important element of its business strategy  the company intends to seek third party financing to support rentals of prep and fpu placements of screen 
there can be no assurance that the company will be able to obtain such financing or  if so  on favorable terms 
failure to obtain such financing could have a material adverse effect on the company s business  financial condition and results of operations 
future revenues and results of operations may fluctuate significantly from quarter to quarter and will depend upon  among other factors  the timing and outcome of the fda review of the prep pma amendment and the screen pma amendment  the extent to which the company s products gain market acceptance  the timing and volume of sales and rental orders  regulatory and reimbursement matters  introduction of alternative technologies by competitors  pricing of competitive products  and the cost and effect of promotional discounts and marketing programs adopted by the company 
the company anticipates that if fda approval is received to market prep for gynecological uses  its marketing and sales expenditures will increase significantly 
the company also anticipates that research and development expenses  both in the areas of product enhancement and new product development  and manufacturing expenses will also increase as product commercialization increases 
the company additionally expects to incur compensation expense of million as its deferred compensation balance is amortized 
results of operations years ended december  and net sales and gross profit 
net sales increased by from million in to million in the increase was due to higher sales of prep units and related consumables and an increase in pathology workstation related sales 
included in pathology workstation revenues in was  of revenue recognized pursuant to a world wide distribution agreement for imagetiter r  the company s product that enables the quantitative assessment of anti nuclear antibodies in a patient s blood specimen 
the company s gross profit during was million  or of sales  an increase from  or of sales  in this increase was due to the increased sales of prep consumables  as well as improved margins on pathology workstation products that primarily resulted from the high margin on the imagetiter r distribution agreement revenue 
total operating expenses 
operating expenses increased by from million in to million in research and development costs for were million  an increase of  from million in  due primarily to increased regulatory expenses associated with the prep and screen products 
selling  general and administrative sg a costs for were million  an increase of  from million in  due primarily to higher costs as the company increased its staffing levels and other expenditures to support product commercialization 
interest income and interest expense  including credit agreement commitment fee 
interest income for was million  an increase of from  in  primarily attributable to the short term investment of proceeds from the company s initial public offering in september interest expense for was  a decrease from million in the significant interest expense in was due to the one time  non cash expense resulting from the issuance of warrants as a commitment fee for a credit agreement between the company and certain of its principal stockholders 
years ended december  autocyte and december  pro forma combined net sales and gross profit 
net sales increased by from million in to million in the increase was primarily attributable to a million increase in prep revenue from  in to million in as the company increased the number of prep placements in the united states and international markets 
this increase was partially offset by a  decrease in sales of pathology workstation products from million in to million in this decrease was a result of management s decision to focus on development and sales of prep and screen products 
additionally  screen revenues increased to  in from in  resulting from foreign placements 
gross profit increased by million from a loss of million in to gross profit of  the loss in was due primarily to the write off of obsolete inventory by the company s predecessor of million in the fourth quarter of as a result of management s decision to focus on development and sales of prep and screen products 
total operating expenses 
operating expenses decreased by from million in to in research and development costs remained relatively flat  increasing from million in to million in sg a costs decreased by from million in to million in due primarily to the write down of property and equipment by the company s predecessor of million in the fourth quarter of  and other acquisition related one time charges in the fourth quarter of of million 
during the company granted options under the equity incentive plan to acquire  shares of common stock at an exercise price of per share 
the company also sold to certain members of management  shares of series a preferred stock at a price of per share 
the company recorded million of deferred compensation expense and  of compensation expense with respect to these transactions 
the company also recorded  of amortization of deferred compensation expense during interest income and interest expense  including credit agreement commitment fee 
on june  the company issued warrants to acquire  shares of common stock at an exercise price of per share as a commitment fee for a credit agreement among the company and certain of its principal stockholders 
the company recorded million of commitment fee expense with respect to this transaction  all of which was expensed in june this increase in interest expense was partially offset by an increase in interest income of  which was primarily attributable to the investment of the proceeds from the company s initial public offering 
income taxes the company has not generated any taxable income to date and  therefore  has not paid any federal income taxes since its inception 
realization of deferred tax assets is dependent on future earnings  if any  the timing and amount of which are uncertain 
accordingly  valuation allowances  in amounts equal to the net deferred tax assets as of december  and  have been established in each period to reflect these uncertainties 
at december   the company had net operating losses  for tax purposes  of approximately million that may be carried forward to offset future taxable income 
this amount expires in through utilization of net operating losses and any tax credit carryforwards are subject to complex treatment under the internal revenue code of  as amended the code 
pursuant to section of the code  the change in ownership resulting from the company s initial public offering in september and any other future sale of stock may limit utilization of future losses in any one year 
the company believes that the sale of common stock in the offering did not create any immediate limitations on the company s utilization of net operating losses 
year readiness disclosure the company has established a task force comprised of experienced personnel from all functional areas of the company to determine the impact the year problem will have on its operations 
the task force s activities are designed to ensure that there is no adverse effect on the company s core business operations and that transactions with customers and suppliers are fully supported before  during and after january  the task force is focusing its efforts on five key areas products  information technology it systems  vendors and service providers  telecommunications  and facilities  including non it systems 
the company is well underway with these efforts  and anticipates achieving year readiness  including the development of a contingency plan  by september  all shipments of prep units made subsequent to september  are year compliant  and the company is upgrading non compliant units in the field in conjunction with routine preventative maintenance visits 
most of the company s pathology workstation products are currently year compliant  and the company is currently determining an appropriate course of action to deal with non compliant products 
the company expects to complete its assessment of screen by june  the company believes that the majority of its internal systems are year compliant  and has initiated correspondence with significant suppliers  large customers and financial institutions to ensure that those parties have appropriate plans to remediate year issues where their systems could effect the company s operations 
while the company believes its planning efforts are adequate to address its year concerns  there can be no guarantee that systems of other companies on which the company relies will be converted on a timely basis and will not have a material effect on the company  or that the company will ever achieve year readiness 
the company is dependent on certain sole source suppliers 
failure on the part of those suppliers to become year compliant could affect the ability of the company to obtain product from those suppliers and could adversely affect operations and financial results 
to date  the company has not incurred material costs in addressing the year  and the remaining costs of the year initiatives are not expected to be material to the company s results of operation or financial position 
recently issued accounting standards effective january   the company adopted statement of financial accounting standards no 
 reporting comprehensive income sfas 
sfas establishes standards for reporting and display of comprehensive income and its components in financial statements 
the application of the new rules did not have an impact on the company s financial statements since it has no items of other comprehensive income in any period presented 
effective january   the company adopted statement of financial accounting standards no 
 disclosures about segments of an enterprise and related information sfas 
sfas changes the way public companies report segment information in annual financial statements and also requires those companies to report selected segment information in interim financial statements to shareholders 
sfas also establishes standards for related disclosures about products and services  geographic areas  and major customers 
the application of the new rules did not have an impact on the company s financial statements as the company operates in only one business segment 
in june  the fasb issued statement of financial accounting standards no 
 accounting for derivative instruments and hedging activities sfas  which is effective for years beginning after june  sfas establishes a comprehensive and consistent standard for the recognition and measurement of derivatives and hedging activities 
the company will adopt sfas in  which may result in additional disclosures 
the application of the new rules is not expected to have a significant impact on the company s financial position or results from operations 
liquidity and capital resources since its formation on october   the company s expenses have significantly exceeded its revenues  resulting in an accumulated deficit of million as of december  the company has funded its operations primarily through the private placement and public sale of equity securities  resulting in net proceeds of million  debt facilities and limited product sales 
as of december   the company had cash and cash equivalents of million 
cash used in the company s operations was million in  million during and million on a pro forma combined basis during negative operating cash flow during  and was caused primarily by operating losses 
the company s capital expenditures were million in  million during and  on a pro forma combined basis during  with the increases primarily attributable to the purchase of prep units for rental and demonstration purposes 
the company has no material commitments for capital expenditures 
the company believes that its existing cash and anticipated additional debt and lease financing for internal use assets  rental placements of prep and fee per use placements of screen if and when fda approval is received  will be sufficient to enable the company to meet its future cash obligations through the company s future liquidity and capital requirements will depend upon numerous factors  including the timing of the company s receipt of fda approval of its pma for prep  the availability of financing for the company s anticipated equipment lease and rental programs  the level of placements of rental prep systems and fee per use screen systems  the resources required to further develop its marketing and sales capabilities domestically and internationally  the resources required to expand manufacturing capacity and the extent to which the company s products generate market acceptance and demand 
in particular  if the fda approves the prep pma  the company anticipates that marketing and sales expenditures for the prep market launch for gynecological uses in the united states  capital expenditures associated with placements of prep rental units  and expenditures related to manufacturing and other administrative costs will increase significantly 
there can be no assurance that the company will not require additional financing or will not in the future seek to raise additional funds through bank facilities  debt or equity offerings or other sources of capital 
additional funding may not be available when needed or on terms acceptable to the company  which would have a material adverse effect on the company s business  financial condition and results of operations 
the discussion included in this section as well as elsewhere in the annual report on form k may contain forward looking statements based on current expectation of the company s management 
such statements are subject to risks and uncertainties that could cause actual results to differ from those projected 
see important factors regarding forward looking statements attached hereto as exhibit and incorporated by reference into this form k 
readers are cautioned not to place undue reliance on the forward looking statements  which speak only as the date hereof 
the company undertakes no obligation to publicly release the result of any revisions to these forward looking statements that may be made to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events 
item a 
quantitative and qualitative disclosure about market risk the company s financial results and cash flows are subject to fluctuation due to changes in interest rates  primarily from its investment of available cash balances in highly rated institutions 
under its current policies  the company does not use interest rate derivative instruments to manage exposure to interest rate changes 

